Target Catecholamine synthesis (FDOPA)Class Amino acid (L-DOPA analogue)Other names 6-fluoro-L-DOPA, fluorodopa
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [¹⁸F]FDOPA Syntheses and QC ↗ | Imaging | 214.18 | 13 | Phase 3 | FDOPA (Feinstein, IASOdopa, Dopacis…) US EU FR |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| [18F]FDOPANCT04706910 · Parkinson's disease and parkinsonian syndromes | Phase 3 | Recruiting | University of Alberta | 1 |
| KING · [18F]FDOPANCT05512403 · Brain (glioma, medulloblastoma…) | Phase 3 | Recruiting | Central Hospital, Nancy, France | 1 |
| [68Ga]Ga-DOTA-TATE/TOC/NOCNCT02019706 · Adrenal | Phase 2 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| DOPA PET · [18F]FDOPANCT04205604 · Hyperinsulinism and insulinoma | Phase 2 | Recruiting | Miguel Pampaloni | 1 |
| FdopaPD2 · [18F]FDOPANCT04459052 · Parkinson's disease and parkinsonian syndromes | Phase 2 | Active, not recruiting | Thomas Jefferson University | 1 |
| [18F]FDOPANCT07542158 · Parkinson's disease and parkinsonian syndromes | Phase 2 | By invitation | Akiva Mintz | 1 |
| 18FDOPA HI · [18F]FDOPANCT05088798 · Hyperinsulinism and insulinoma | Phase 2 | Recruiting | Washington University School of Medicine | 1 |
| [18F]FDOPANCT05255159 · NETs and neuroendocrine carcinomas (other) | Phase 2 | Active, not recruiting | University of Alberta | 1 |
| [18F]FDOPANCT06667726 · Brain (glioma, medulloblastoma…) | Phase 2 | Recruiting | Mayo Clinic | 1 |
| [18F]FDOPANCT02021604 · Hyperinsulinism and insulinoma | Phase 1 | Recruiting | Cook Children's Health Care System | 1 |
| [18F]FDOPANCT04246437 · Alzheimer's disease and cognitive disorders | Phase 1 | Recruiting | Daniel Claassen | 1 |
| [18F]FDOPANCT03541720 · Neuroblastoma | Phase 1 | Active, not recruiting | St. Jude Children's Research Hospital | 1 |
| EARLYBRAINPET · [18F]FDOPANCT07274397 · Brain (glioma, medulloblastoma…) | No phase | Recruiting | Beta Emitting Accurate Monitored Systems | 1 |
| ADACHOL · Brain receptors, transporters and enzymesNCT03998852 · Other | Phase 3 | Recruiting | University Hospital, Bordeaux | 1 |
| CT1-DAP001 · [18F]FEPPANCT06482268 · Parkinson's disease and parkinsonian syndromes | Phase 1 | Recruiting | University of California, San Diego | 1 |
| 2026-06 | FDOPA in medullary thyroid cancer · positiveMulticentre study in 24 patients with raised calcitonin after surgery: FDOPA PET detects 1.5 times more metastatic lymph nodes than conventional imaging and changes management in 58% of cases. Reading is demanding, with a learning curve. | Eur J Nucl Med Mol Imaging ↗ |
1,686 publications in PubMed for the query below; the most recent:
FDOPA[tiab] OR fluorodopa[tiab] OR "F-DOPA"[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
FDOPA. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fdopa/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.